These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38750702)

  • 21. Therapeutic effects of Wharton's jelly-derived Mesenchymal Stromal Cells on behaviors, EEG changes and NGF-1 in rat model of the Parkinson's disease.
    Jalali MS; Saki G; Farbood Y; Azandeh SS; Mansouri E; Ghasemi Dehcheshmeh M; Sarkaki A
    J Chem Neuroanat; 2021 Apr; 113():101921. PubMed ID: 33600923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration.
    Hurtado-Lorenzo A; Millan E; Gonzalez-Nicolini V; Suwelack D; Castro MG; Lowenstein PR
    Mol Ther; 2004 Sep; 10(3):507-24. PubMed ID: 15336651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decreased synaptic plasticity in the medial prefrontal cortex underlies short-term memory deficits in 6-OHDA-lesioned rats.
    Matheus FC; Rial D; Real JI; Lemos C; Ben J; Guaita GO; Pita IR; Sequeira AC; Pereira FC; Walz R; Takahashi RN; Bertoglio LJ; Da Cunha C; Cunha RA; Prediger RD
    Behav Brain Res; 2016 Mar; 301():43-54. PubMed ID: 26707254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
    Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
    Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
    Ramírez-García G; Palafox-Sánchez V; Limón ID
    Neuroscience; 2015 Apr; 290():492-508. PubMed ID: 25644418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular insulin-like growth factor-1 gene therapy modulates reactive microglia after traumatic brain injury.
    Herrera ML; Bandín S; Champarini LG; Hereñú CB; Bellini MJ
    Brain Res Bull; 2021 Oct; 175():196-204. PubMed ID: 34339780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beneficial effect of etazolate on depression-like behavior and, learning, and memory impairment in a model of Parkinson's disease.
    Alzoubi KH; Mokhemer E; Abuirmeileh AN
    Behav Brain Res; 2018 Sep; 350():109-115. PubMed ID: 29758248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rejuvenating Effect of Long-Term Insulin-Like Growth Factor-I Gene Therapy in the Hypothalamus of Aged Rats with Dopaminergic Dysfunction.
    Schwerdt JI; Lopez-Leon M; Cónsole GM; Brown OA; Morel GR; Spinedi E; Goya RG
    Rejuvenation Res; 2018 Apr; 21(2):102-108. PubMed ID: 28673122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis.
    Carmo MR; Menezes AP; Nunes AC; Pliássova A; Rolo AP; Palmeira CM; Cunha RA; Canas PM; Andrade GM
    Neuropharmacology; 2014 Jun; 81():142-52. PubMed ID: 24508709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
    Silva C; Fuxe K; Chadi G
    J Neural Transm Suppl; 2009; (73):185-202. PubMed ID: 20411778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive and anxiety-like impairments accompanied by serotonergic ultrastructural and immunohistochemical alterations in early stages of parkinsonism.
    Leal PC; Bispo JMM; Lins LCRF; Souza MF; Gois AM; Moore C; Marchioro M; Ribeiro AM; Silva RH; Meshul CK; Santos JR
    Brain Res Bull; 2019 Mar; 146():213-223. PubMed ID: 30641120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesencephalic astrocyte-derived neurotrophic factor (MANF) prevents the neuroinflammation induced dopaminergic neurodegeneration.
    Zhang JX; Zhou KG; Yin YX; Jin LJ; Tong WF; Guo J; Yu LH; Ye XC; Jiang M
    Exp Gerontol; 2023 Jan; 171():112037. PubMed ID: 36436758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary 8-OHdG elevations in a partial lesion rat model of Parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion.
    Kikuchi Y; Yasuhara T; Agari T; Kondo A; Kuramoto S; Kameda M; Kadota T; Baba T; Tajiri N; Wang F; Tayra JT; Liang H; Miyoshi Y; Borlongan CV; Date I
    J Cell Physiol; 2011 May; 226(5):1390-8. PubMed ID: 20945350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.
    Yue X; Hariri DJ; Caballero B; Zhang S; Bartlett MJ; Kaut O; Mount DW; Wüllner U; Sherman SJ; Falk T
    Neuroscience; 2014 Jan; 258():385-400. PubMed ID: 24291725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
    Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
    Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastric dysregulation induced by microinjection of 6-OHDA in the substantia nigra pars compacta of rats is determined by alterations in the brain-gut axis.
    Toti L; Travagli RA
    Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G1013-23. PubMed ID: 25277799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the iNOS isoform in the cardiovascular dysfunctions of male rats with 6-OHDA-induced Parkinsonism.
    de Jager L; Vidigal CB; de Campos BH; Reginato GS; Fernandes LM; Ariza D; Higashi-Mckeown CM; Bertozzi MM; Rasquel de Oliveira FS; Verri WA; Ceravolo GS; Crestani CC; Pinge-Filho P; Martins-Pinge MC
    Nitric Oxide; 2023 May; 134-135():49-60. PubMed ID: 37054808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nasal application of kisspeptin-54 mitigates motor deficits by reducing nigrostriatal dopamine loss in hemiparkinsonian rats.
    Sinen O; Sinen AG; Derin N; Aslan MA
    Behav Brain Res; 2024 Jun; 468():115035. PubMed ID: 38703793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of bromelain on motor responses following intra-medial forebrain bundle 6-OHDA injection in rat model of parkinsonism.
    Adu TS; Mabandla MV
    Metab Brain Dis; 2019 Dec; 34(6):1557-1564. PubMed ID: 31332728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.